Frontiers Case report: Short-term eculizumab use in atypical HUS

PDF] Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study, BMC Nephrology

Frontiers Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis

Frontiers Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

PDF) A systematic review on the efficacy and safety of eculizumab for atypical hemolytic uremic syndrome

PDF) Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome

Frontiers Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report

PDF) First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient

PDF) A systematic review on the efficacy and safety of eculizumab for atypical hemolytic uremic syndrome